newsfilter
← Latest News
GlobeNewswire·

Eton Pharmaceuticals Announces Preliminary ET-700 Pilot Study Results Evaluating Copper Absorption Inhibition and Gastrointestinal Tolerability

Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN® participantsHepatic copper uptake decreased 12% with ET-700, compared with a 46% decrease with GALZIN, and an 11%